Invasive Candidiasis
1
Pipeline Programs
3
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
ScynexisIbrexafungerp
Allergy Therapeuticstherapy duration
PfizerDoes not apply
Clinical Trials (3)
Total enrollment: 536 patients across 3 trials
Study to Evaluate the Efficacy and Safety of Ibrexafungerp in Patients With Fungal Diseases That Are Refractory to or Intolerant of Standard Antifungal Treatment
Start: Apr 2017Est. completion: Aug 2023
Phase 3Completed
Comparison of Uncomplicated Candidemia Therapy Duration in Children
Start: Sep 2023Est. completion: Jun 2032
N/ARecruiting
Risk Of Severe Hepatic Injury In Patients With Invasive Candidiasis Treated With Echinocandins
Start: Sep 2008Est. completion: May 2011536 patients
N/ATerminated
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 536 patients
3 companies competing in this space